Treatment plans are tailored based on specific molecular subtypes, such as hormone receptor-positive patients requiring endocrine therapy (some patients also receiving chemotherapy), HER2-positive patients receiving HER2-targeted antibody therapy, often combined with chemotherapy, and triple-negative breast cancer primarily treated with chemotherapy. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.